WEBSITE BSE:0 NSE: Inc. Year: 2005 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:40
No Notes Added Yet
Onyx Biotec Limited is a biotechnology company primarily focused on developing and providing innovative solutions in the healthcare and life sciences sectors. The company specializes in research, manufacturing, and the distribution of high-quality biotechnological products. Its offerings are geared towards improving healthcare through the development of advanced therapeutic treatments, diagnostics, and medical devices. With a strong commitment to research and development, Onyx Biotec Limited continues to explore cutting-edge technologies aimed...Read More
Onyx Biotec Limited is a biotechnology company primarily focused on developing and providing innovative solutions in the healthcare and life sciences sectors. The company specializes in research, manufacturing, and the distribution of high-quality biotechnological products. Its offerings are geared towards improving healthcare through the development of advanced therapeutic treatments, diagnostics, and medical devices. With a strong commitment to research and development, Onyx Biotec Limited continues to explore cutting-edge technologies aimed at addressing critical health challenges. The company's portfolio includes a variety of products designed to support the medical and pharmaceutical industries, enhancing patient care and treatment outcomes. Its dedication to quality assurance and regulatory compliance ensures that all products meet international standards, making it a trusted name in the biotech field. Through its continued growth and innovation, Onyx Biotec is positioning itself as a leader in the biotechnology industry, with a strong focus on sustainability and enhancing human health. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹63 Cr.
Stock P/E 12.7
P/B 1.1
Current Price ₹34.7
Book Value ₹ 30.7
Face Value 10
52W High ₹56
Dividend Yield 0%
52W Low ₹ 28.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 45 | 39 | 54 | 62 | |
| Other Income | 0 | 0 | 0 | 1 | |
| Total Income | 45 | 40 | 54 | 63 | |
| Total Expenditure | 39 | 35 | 45 | 52 | |
| Operating Profit | 6 | 5 | 9 | 12 | |
| Interest | 1 | 1 | 2 | 2 | |
| Depreciation | 1 | 1 | 2 | 3 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 4 | 3 | 4 | 6 | |
| Provision for Tax | 0 | 1 | 1 | 2 | |
| Profit After Tax | 3 | 2 | 4 | 5 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 3 | 2 | 4 | 5 | |
| Adjusted Earnings Per Share | 2.8 | 1.6 | 2.7 | 2.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 11% | 0% | 0% |
| Operating Profit CAGR | 33% | 26% | 0% | 0% |
| PAT CAGR | 25% | 19% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -32% | NA% | NA% | NA% |
| ROE Average | 12% | 13% | 15% | 15% |
| ROCE Average | 14% | 12% | 13% | 13% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 16 | 18 | 25 | 56 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 9 | 18 | 24 | 7 |
| Other Non-Current Liabilities | 2 | 2 | 3 | 3 |
| Total Current Liabilities | 10 | 20 | 23 | 26 |
| Total Liabilities | 37 | 59 | 74 | 91 |
| Fixed Assets | 17 | 43 | 43 | 41 |
| Other Non-Current Assets | 5 | 2 | 1 | 1 |
| Total Current Assets | 14 | 15 | 30 | 49 |
| Total Assets | 37 | 59 | 74 | 91 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 1 |
| Cash Flow from Operating Activities | 0 | 6 | 2 | 1 |
| Cash Flow from Investing Activities | -6 | -23 | -3 | 1 |
| Cash Flow from Financing Activities | 5 | 16 | 3 | 5 |
| Net Cash Inflow / Outflow | -0 | -0 | 1 | 7 |
| Closing Cash & Cash Equivalent | 0 | 0 | 1 | 9 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.84 | 1.56 | 2.73 | 2.73 |
| CEPS(Rs) | 4.07 | 2.83 | 4.13 | 4.41 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 13.87 | 15.42 | 18.98 | 30.68 |
| Core EBITDA Margin(%) | 12.87 | 11.37 | 15.61 | 16.74 |
| EBIT Margin(%) | 9.9 | 7.91 | 12.37 | 13.71 |
| Pre Tax Margin(%) | 8.46 | 6.45 | 8.35 | 10.46 |
| PAT Margin (%) | 7.47 | 4.67 | 6.76 | 8 |
| Cash Profit Margin (%) | 10.7 | 8.45 | 10.24 | 12.92 |
| ROA(%) | 9.1 | 3.86 | 5.47 | 5.99 |
| ROE(%) | 20.47 | 10.67 | 16.71 | 12.25 |
| ROCE(%) | 15.52 | 8.21 | 12.85 | 13.68 |
| Receivable days | 68.49 | 62.37 | 69.43 | 104.89 |
| Inventory Days | 24.84 | 43.36 | 52.4 | 74.24 |
| Payable days | 59.4 | 97.57 | 105.74 | 142.32 |
| PER(x) | 0 | 0 | 0 | 21.23 |
| Price/Book(x) | 0 | 0 | 0 | 1.89 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.4 | 0.89 | 0.79 | 1.76 |
| EV/Core EBITDA(x) | 3.08 | 7.61 | 5.01 | 9.45 |
| Net Sales Growth(%) | 0 | -11.99 | 36.14 | 15.26 |
| EBIT Growth(%) | 0 | -29.75 | 112.96 | 27.78 |
| PAT Growth(%) | 0 | -44.98 | 97.04 | 36.31 |
| EPS Growth(%) | 0 | -44.98 | 74.57 | 0.15 |
| Debt/Equity(x) | 0.75 | 1.61 | 1.22 | 0.22 |
| Current Ratio(x) | 1.44 | 0.72 | 1.31 | 1.91 |
| Quick Ratio(x) | 1.17 | 0.42 | 0.91 | 1.29 |
| Interest Cover(x) | 6.86 | 5.43 | 3.08 | 4.21 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.12 |
| # | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 65.1 | 65.1 | 65.1 |
| FII | 5.36 | 1.95 | 1.07 |
| DII | 2.39 | 2.39 | 2.39 |
| Public | 27.15 | 30.56 | 31.44 |
| Others | 0 | 0 | 0 |
| Total | 100 | 100 | 100 |
| # | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 1.18 | 1.18 | 1.18 |
| FII | 0.1 | 0.04 | 0.02 |
| DII | 0.04 | 0.04 | 0.04 |
| Public | 0.49 | 0.55 | 0.57 |
| Others | 0 | 0 | 0 |
| Total | 1.81 | 1.81 | 1.81 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
